問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5272Cases

2025-06-15 - 2027-04-17

Phase III

Active
A phase 3, external and synthetic placebo-controlled randomized trial, with dose escalation in non-responders, investigated the safety and efficacy of RITLECITINIB 50 mg and 100 mg once daily in adults and adolescents aged 12 years and older with alopecia areata.

  • Condition/Disease

    Suitable for treating patients aged 12 years and older with severe alopecia areata.

  • Test Drug

    Ritlecitinib

Participate Sites
5Sites

Recruiting5Sites

2025-06-30 - 2032-05-01

Phase II

Active
A phase 2, open-label, multi-population trial evaluating the efficacy and safety of ASP5541 in participants with advanced prostate cancer.

  • Condition/Disease

    * Percentage of mCRPC participants who have not used ARPI and whose PSA has decreased by ≥90% from baseline.* Incidence of no mineral corticosteroid toxicity (defined as no ≥ Grade 1 hypokalemia and no ≥ Grade 2 hypertension).* Percentage of mHSPC participants with PSA ≤ 0.2 ng/mL at 8 months.* DLT, AE, SAE, laboratory test results (including chemistry, hematology, and urinalysis), ECG, vital signs, physical examination, and ECOG performance status score.

  • Test Drug

    "Chengda" Prednisone Tablets 5 mg (Penisol) "Boli" Concentrate Tablets 5 mg (Penisol) Abiraterone acetate ASP5541 (Abiraterone decanoate) Cosyntropin Prednisone Abiraterone Tablets 250 mg Prednisone Tablets Erezhi Film-Coated Tablets 250 mg Lerdan Tablets

Participate Sites
6Sites

Recruiting6Sites

2025-06-30 - 2027-07-28

Phase III

Active
A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of lebrikizumab in adult and adolescent participants with moderate to severe atopic dermatitis of the hands and feet.

  • Condition/Disease

    Moderate to severe atopic dermatitis of the hands and feet

  • Test Drug

    EBGLYSS Injection

Participate Sites
7Sites

Recruiting7Sites

2025-07-01 - 2029-06-30

Phase II

Active
Clinical trial of PVX4 for the treatment of HPV16-positive cervical intraepithelial neoplasia

  • Condition/Disease

    Human papillomavirus type 16 (HPV) type 16 (HPV type 16) cervical precancerous lesions (HPV type 16, HPV type 16, HPV type 2, HPV type 3, HPV type 3)

  • Test Drug

    PVX4

Participate Sites
9Sites

Recruiting9Sites

2025-07-01 - 2030-12-31

Active
A phase III, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy of AZD0780 in patients with established atherosclerotic cardiovascular disease (ASCVD) or at high risk of first ASCVD events for major adverse cardiovascular events.

  • Condition/Disease

    Patients with established atherosclerotic cardiovascular disease or at high risk of their first atherosclerotic cardiovascular event.

  • Test Drug

    AZD0780

Participate Sites
23Sites

Recruiting23Sites

2025-07-01 - 2028-12-31

Phase III

Active
A randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of Baxdrostat in adult subjects with primary hyperaldosteronism.

  • Condition/Disease

    - Changes in sit-and-reach systolic blood pressure (SBP) at week 8 since baseline - Subjects whose plasma renin activity (PRA) was suppressed (< 1 μg/L/h) at baseline achieved unsuppressed plasma renin activity (PRA) (≥ 1 μg/L/h) at week 8.

  • Test Drug

    Baxdrostat

Participate Sites
6Sites

Recruiting6Sites

2025-07-15 - 2029-11-13

Phase II/III

Active
A randomized, phase 2/3 trial was conducted in treatment-naïve patients with homologous MTAP deficiency in metastatic pancreatic ductal adenocarcinoma. The efficacy of BMS-986504 combined with Nab-paclitaxel and Gemcitabine was compared with placebo combined with Nab-paclitaxel and Gemcitabine.

  • Condition/Disease

    Metastatic pancreatic duct adenocarcinoma

  • Test Drug

    BMS-986504

Participate Sites
4Sites

Recruiting4Sites

2025-07-31 - 2028-09-01

Phase III

Active
A phase 3, open-label, two-group interventional trial investigating the efficacy and safety of fosmanogepix in adult patients with invasive fungal infections caused by Aspergillus, Fusarium, Lomentospora prolificans, Mucorales fungi, or other multidrug-resistant fungi.

  • Condition/Disease

    Invasive fungal infection

  • Test Drug

    Fosmanogepix Fosmanogepix

Participate Sites
8Sites

Recruiting8Sites

2025-07-31 - 2029-12-31

Phase III

Active
A phase 3, randomized, placebo-controlled, double-blind trial to evaluate the safety, tolerability, and immunogenicity of a multivalent group B streptococcal vaccine in healthy pregnant women and their infants

  • Condition/Disease

    • Prespecified local reactions (redness, swelling, and pain at the injection site). • Prespecified systemic events (fever, nausea/vomiting, diarrhea, headache, fatigue, muscle pain, and joint pain). • Adverse events (AEs). • Serious Adverse Events (SAEs). • Adverse events requiring medical attention (MAAE).

  • Test Drug

    PF-06760805

Participate Sites
4Sites

Recruiting4Sites

2025-08-01 - 2032-12-31

Phase III

Active
AcTFirst: A phase III, open-label, multicenter, randomized trial comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration-resistant prostate cancer

  • Condition/Disease

    rPFS was defined as the time elapsed from the date of randomization to the date of the first documented radiographic disease progression or death from any cause as assessed by the Blinded Independent Central Review Committee (BICR) using conventional imaging and Prostate Cancer Working Group 3 (PCWG3) revised RECIST version 1.1 criteria, whichever occurred first.

  • Test Drug

    AAA617 AAA817 Abiraterone Cabazitaxel

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 528
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB